Dr. Ott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana 2127
Boston, MA 02215Phone+1 617-582-9030Fax+1 212-263-6727
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 2012 - 2026
NY State Medical License 2008 - 2013
OH State Medical License 2002 - 2005
Clinical Trials
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma Start of enrollment: 2014 Jan 01
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
- Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2014 May 01
- Join now to see all
Publications & Presentations
PubMed
- Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.Karam Khaddour, Rizwan Haq, Elizabeth I Buchbinder, David Liu, Michael P Manos
The Oncologist. 2024-11-06 - Advances in Vaccines for Melanoma.Can Cui, Patrick A Ott, Catherine J Wu
Hematology/oncology Clinics of North America. 2024-10-01 - Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.Anna K Maloney, Anita Giobbie-Hurder, Nikita Katukota, Miklos C Fogarasi, Patrick A Ott
Journal for Immunotherapy of Cancer. 2024-08-28
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
- Pembrolizumab for Advanced Prostate Adenocarcinoma: Findings of the KEYNOTE-028 StudyM Gould, P Yang, P A Ott, Annals of Oncology
- A Cloning and Expression System to Probe T Cell Receptor Specificity and Assess Functional Avidity to NeoantigensWilliam J Lane, Patrick A Ott, Catherine J Wu, Donna E Leet, Blood
Press Mentions
Vaccine Slows Return of Pancreatic Cancer in Early TrialMay 11th, 2023- Pancreatic Cancer Vaccine Shows Promise in Small TrialMay 10th, 2023
- Experimental Cancer Vaccine Combined with Immunotherapy Delayed Return of Melanoma, Moderna and Merck SayApril 17th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
